Dr David Kaslow, Vice President of Infectious Diseases and Vaccines at Merck to give Keynote presentation at 3rd Modern Drug Discovery and Development Summit
Released on: October 17, 2007, 9:17 am
Press Release Author: GTCbio
Industry: Biotech
Press Release Summary: Dr. David Kaslow, VP of Infectious Diseases and Vaccines at Merck will give the Keynote presentation at GTCbio's Biological Therapeutics conference - one of six tracks at the 3rd Modern Drug Discovery & Development Summit on November 28-30, 2007 at the Hyatt Regency San Francisco Airport.
Press Release Body: MONROVIA, CA - Dr. David Kaslow, Vice President of Infectious Diseases and Vaccines at Merck & Company will give the Keynote presentation at GTCbio's Biological Therapeutics conference - one of six tracks at the 3rd Modern Drug Discovery & Development Summit on November 28-30, 2007 at the Hyatt Regency San Francisco Airport.
Dr. Kaslow's presentation will cover the progress toward a multi-dimensional approach to infectious diseases product development by integrating diagnostics, drugs, and biologics. Historically, anti-infectives and biologics (antibodies and vaccines), in addition to general public health measures, have had an immense impact on alleviating the healthcare burden due to infectious diseases. With perhaps a few exceptions (e.g., Variola), however, each new specific therapeutic advance has been ultimately met by some counter-response from the microbial world. Given those conditions, it should come as no surprise that although a single dimensional therapeutic approach may provide a near-term gain, such an approach wills an unlikely result in a durable effective intervention. A multi-dimensional approach, which may include diagnostics, drugs and biologics, to prevent and/or treat infections by these evolving microbial pathogens may be necessary to add new products with real, long-lasting value to our armamentarium. Building an integrated approach by appropriately incorporating new diagnostics and integrating multiple interventional modalities may provide a more valuable and sustainable next generation of products. Examples of such approaches will be presented.
The 3rd Modern Drug Discovery & Development Summit features over 150 speakers participating in 6 concurrent conferences, 6 study sessions and 3 pre-conference workshops. Tracks include Biological Therapeutics, Drug Delivery Technology, Translational Medicine, Drug Design and Lead Optimization, Emerging Targets, and Pharmaco - Kinetics, Dynamics, Genomics and Genetics. For more information, visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
2025
